| Nr. | Year OPEN | Title | users say | rate good | rate bad | no link | Citation |
|---|
MetforminHormesisChemopreventionPolycystic ovary syndromeInsulin resistanceAMP activated protein kinaseMammary gland (Neoplasia)| 1 | 1977 | Biguanides and lactic acidosis in diabetics. | 
| + | - | nl | Br Med J 2(6100):1436 (1977) |
| 2 | 2003 | Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus: systematic review and meta-analysis. |
| + | - | nl | Arch Intern Med 163(21):2594-602 (2003) |
| 3 | 2002 | Evaluation of prescribing practices: risk of lactic acidosis with metformin therapy. |
| + | - | nl | Arch Intern Med 162(4):434-7 (2002) |
| 4 | 2004 | The effect of metformin on blood pressure, plasma cholesterol and triglycerides in type 2 diabetes mellitus: a systematic review. |
| + | - | nl | J Intern Med 256(1):1-14 (2004) |
| 5 | 2004 | Metformin and lactic acidosis: cause or coincidence? A review of case reports. |
| + | - | nl | J Intern Med 255(2):179-87 (2004) |
| 6 | 2008 | Reality of severe metformin-induced lactic acidosis in the absence of chronic renal impairment. |
| + | - | nl | Neth J Med 66(5):185-90 (2008) |
| 7 | 2002 | Metformin: evidence-based versus rational pharmacotherapy. |
| + | - | nl | Neth J Med 60(6):228-30 (2002) |
| 8 | 2009 | Treating prediabetes with metformin: systematic review and meta-analysis. |
| + | - | nl | Can Fam Physician 55(4):363-9 (2009) |
| 9 | 2005 | Metformin as treatment for overweight and obese adults: a systematic review. |
| + | - | nl | Ann Fam Med 3(5):457-61 (2005) |
| 10 | 2007 | A review of thiazolidinediones and metformin in the treatment of type 2 diabetes with focus on cardiovascular complications. |
| + | - | nl | Vasc Health Risk Manag 3(6):967-73 (2007) |
| 11 | 2007 | Treatment update: thiazolidinediones in combination with metformin for the treatment of type 2 diabetes. |
| + | - | nl | Vasc Health Risk Manag 3(4):503-10 (2007) |
| 12 | 2009 | ACP Journal Club. Review: Metformin reduces risk for CV mortality compared with other oral diabetes drugs or placebo in type 2 diabetes. |
| + | - | nl | Ann Intern Med 150(8):JC4-8 (2009) |
| 13 | 2002 | Metformin: an update. |
| + | - | nl | Ann Intern Med 137(1):25-33 (2002) |
| 14 | 2002 | Combination of insulin and metformin in the treatment of type 2 diabetes. |
| + | - | nl | Diabetes Care 25(12):2133-40 (2002) |
| 15 | 1999 | First 20 months' experience with use of metformin for type 2 diabetes in a large health maintenance organization. |
| + | - | nl | Diabetes Care 22(1):38-44 (1999) |
| 16 | 1999 | Efficacy of metformin in the treatment of NIDDM. Meta-analysis. |
| + | - | nl | Diabetes Care 22(1):33-7 (1999) |
| 17 | 2006 | Metformin: 50 years old, fit as a fiddle, and indispensable for its pivotal role in type 2 diabetes management. |
| + | - | nl | Diabetes Metab 32(6):555-6 (2006) |
| 18 | 2004 | Initiating oral glucose-lowering therapy with metformin in type 2 diabetic patients: an evidence-based strategy to reduce the burden of late-developing diabetes complications. |
| + | - | nl | Diabetes Metab 30(6):509-16 (2004) |
| 19 | 2003 | The potential of metformin for diabetes prevention. |
| + | - | nl | Diabetes Metab 29(4 Pt 2):6S104-11 (2003) |
| 20 | 2003 | Metformin inhibition of glycation processes. |
| + | - | nl | Diabetes Metab 29(4 Pt 2):6S95-103 (2003) |
| 21 | 2003 | Mitochondrial metabolism and type-2 diabetes: a specific target of metformin. |
| + | - | nl | Diabetes Metab 29(4 Pt 2):6S88-94 (2003) |
| 22 | 2003 | Antiatherogenic properties of metformin: the experimental evidence. |
| + | - | nl | Diabetes Metab 29(4 Pt 2):6S71-6 (2003) |
| 23 | 2003 | Do effects on blood pressure contribute to improved clinical outcomes with metformin? |
| + | - | nl | Diabetes Metab 29(4 Pt 2):6S62-70 (2003) |
| 24 | 2003 | Potential contribution of metformin to the management of cardiovascular disease risk in patients with abdominal obesity, the metabolic syndrome and type 2 diabetes. |
| + | - | nl | Diabetes Metab 29(4 Pt 2):6S53-61 (2003) |
| 25 | 2003 | Beneficial effects of metformin on haemostasis and vascular function in man. |
| + | - | nl | Diabetes Metab 29(4 Pt 2):6S44-52 (2003) |
| 26 | 2003 | Improving survival with metformin: the evidence base today. |
| + | - | nl | Diabetes Metab 29(4 Pt 2):6S36-43 (2003) |
| 27 | 2003 | Reducing insulin resistance with metformin: the evidence today. |
| + | - | nl | Diabetes Metab 29(4 Pt 2):6S28-35 (2003) |
| 28 | 2007 | Pharmacogenetics of metformin response: a step in the path toward personalized medicine. |
| + | - | nl | J Clin Invest 117(5):1226-9 (2007) |
| 29 | 2002 | Frequency of inappropriate metformin prescriptions. |
| + | - | nl | JAMA 287(19):2504-5 (2002) |
| 30 | 2005 | Metformin's contraindications: needed for now. |
| + | - | nl | CMAJ 173(5):505-7 (2005) Fantus IG |
| 31 | 2005 | Metformin's contraindications should be contraindicated. |
| + | - | nl | CMAJ 173(5):502-4 (2005) |
| 32 | 2010 | Metformin and contrast media. |
| + | - | nl | Radiology 256(2):672-3; author reply 673 (2010) |
| 33 | 2010 | Systematic review of current guidelines, and their evidence base, on risk of lactic acidosis after administration of contrast medium for patients receiving metformin. |
| + | - | nl | Radiology 254(1):261-9 (2010) Goergen SK |
| 34 | 2003 | Contraindications to the use of metformin. |
| + | - | nl | BMJ 326(7379):4-5 (2003) |
| 35 | 2007 | Metformin, heart failure, and lactic acidosis: is metformin absolutely contraindicated? |
| + | - | nl | BMJ 335(7618):508-12 (2007) |
| 36 | 2010 | Metformin and cancer: doses, mechanisms and the dandelion and hormetic phenomena. | 
| + | - | nl | Cell Cycle 9(6):1057-64 (2010) |
| 37 | 2010 | Metformin: an old medication of new fashion: evolving new molecular mechanisms and clinical implications in polycystic ovary syndrome. | 
| + | - | nl | Eur J Endocrinol 162(2):193-212 (2010) |
| 38 | 2003 | Insulin-lowering agents in the management of polycystic ovary syndrome. |
| + | - | nl | Endocr Rev 24(5):633-67 (2003) |
| 39 | 2009 | Evidence-based and potential benefits of metformin in the polycystic ovary syndrome: a comprehensive review. |
| + | - | nl | Endocr Rev 30(1):1-50 (2009) |
| 40 | 2010 | An energetic tale of AMPK-independent effects of metformin. |
| + | - | nl | J Clin Invest 120(7):2267-70 (2010) |
| 41 | 2010 | Metformin: a therapeutic opportunity in breast cancer. |
| + | - | nl | Clin Cancer Res 16(6):1695-700 (2010) |
| 42 | 2004 | Metformin and serious adverse effects. |
| + | - | nl | Med J Aust 180(2):53-4 (2004) |
| 43 | 2004 | Metformin and serious adverse effects. |
| + | - | nl | Med J Aust 181(1):56 (2004) |
| 44 | 2009 | Metformin is a unique drug. |
| + | - | nl | Can Fam Physician 55(6):589; author reply 589 (2009) |
